C
지아이이노베이션
358570KOSDAQ45.0 / 100
Reference Date: 2026-10-23
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
GI Innovation is a biotechnology company specializing in the development of next-generation immune therapies based on fusion proteins, with key drug pipelines including GI-101, GI-102, GI-301, and GI-108. The company utilizes its proprietary GI-SMART™ platform technology to rapidly develop novel bispecific fusion proteins and has achieved growth through technology transfer collaborations with global partners.
Number of Employees
82people
Average Salary
131.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
4.31Industry Average 1.200.0Point
3.6x industry avg (risky)
ROE
-48.28Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
1.47Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲11921.9% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲12.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -77.1% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (6%, downtrend)
Current 7,790Won52-week high 20,90052-week low 6,820
1-month return1.0Point
1m -13.54% (falling)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-07
- Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (GI102 제1/2상 임상시험계획 변경승인 )2026-10-01